ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk--Long Before the Clinic
AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENS ai ™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials.
Article content
'ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars,' said Dr. Jennifer Bath, President & CEO, IPA. 'With LENS ai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-risk programs early and focus resources on the safest molecules.'
Article content
Late‑stage ADA failures can wipe out $1–2 billion in projected revenue for a single biologic and push launch timelines back 12‑18 months. Yet many programs still lean on time‑intensive lab assays or first‑generation in‑silico screens that look only at peptide‑to‑MHC II binding across a few dozen HLA alleles—leaving large swaths of immune diversity untested and immunogenic 'self/non‑self' checks largely unaddressed.
Article content
LENS ai 's HYFT‑powered, alignment‑free immunogenicity screening compresses that entire workflow into one overnight run. It evaluates nearly 900 HLA variants and performs a whole‑proteome 'humanness' scan at residue resolution, instantly flagging hot‑spots that legacy tools miss. By revealing design‑level fixes before expensive animal studies or repeat GMP production, the platform can shorten pre‑clinical cycles, cut material costs, and de‑risk downstream development—delivering a speed‑and‑breadth advantage unattainable with traditional methods.
Article content
Study Highlights
Article content
217 marketed and clinical-stage antibodies analyzed – the largest public ADA dataset to predict immunogenicity risk
Single composite score tracks clinical reality – enables reliable ADA incidence risk classification; a score ≥ 54 flags high-risk candidates (> 30 % ADA in patients). The discriminative capability is very powerful as indicated by an AUC=0.92.
Alignment-free, HYFT-powered engine – the proprietary screening algorithm combines state-of-the-art MHC II binding with IPA's proprietary HYFT® patterns, enabling whole-proteome humanness assessment without multiple-sequence alignments.
Detailed amino acid and epitope-level immunogenicity 'self' scanning – quickly pinpoints immunogenic hot-spots and suggests sequence edits before expensive wet-lab assays.
Article content
Read the full case study:
Article content
[
Article content
link
Article content
]
Article content
About ImmunoPrecise Antibodies Ltd.
Article content
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology.
Article content
Forward-Looking Statements
Article content
This press release contains forward looking statements within the meaning of applicable United States and Canadian securities laws. Forward looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' 'potential,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. Examples include statements regarding the projected performance, scalability, and market adoption of the Company's LENSai™ Immunogenicity Screening; the ability of its HYFT® powered, alignment free platform to shorten development timelines, reduce program risk, or displace legacy wet lab and multiple sequence alignment methods; the economic impact of early, in-silico ADA prediction on biopharma R&D efficiency; and the Company's broader scientific, commercial, and capital markets objectives.
Article content
Forward looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results could differ materially from those expressed or implied because of factors beyond the Company's control, including the pace of scientific and technological innovation in AI driven drug discovery, the accuracy and regulatory acceptance of in-silico ADA risk screening, competitive shifts as the industry transitions away from MS dependent workflows, customer adoption rates, operational or integration challenges, and changes in economic, market, or regulatory conditions. Additional information about these and other risks and uncertainties is set out in the Company's Annual Report on Form 20F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar. If any of these risks materialize, the Company's actual results, performance, or achievements could vary significantly from those currently anticipated.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Relations Contact
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
19 minutes ago
- National Post
July Issue of Best's Review Ranks Top 20 Global Brokers and More
Article content OLDWICK, N.J. — The July issue of Best's Review includes the following exclusive rankings: Article content Top 20 Global Brokers – 2025 Edition Top 200 US Property/Casualty Writers – 2025 Edition Top 200 US Life/Health Insurers – 2025 Edition Top 75 U.S. and Canada Public Insurers – 2025 Edition Ranked by 2024 assets. Ranked by 2024 revenue. World's Largest Insurance Companies – 2025 Edition Ranked by 2023 net nonbanking assets. Ranked by 2023 net premiums written. Top 25 U.S. Holding Companies – 2025 Edition Ranked by 2024 total assets. Ranked by 2024 total revenue. Article content Article content Best's Review Article content is Article content AM Best Article content 's monthly insurance magazine, covering emerging issues and trends and evaluating their impact on the marketplace. Access to the complete content of Article content Best's Review Article content is available Article content here Article content . Article content For Best's Review advertising opportunities and a complete media kit, visit AM Best Advertising Services. Article content . Article content Article content Article content Article content Article content Contacts Article content Patricia Vowinkel Article content Article content Article content
CTV News
19 minutes ago
- CTV News
The issues with using AI to drive dynamic pricing
This week on the 'Wonk' podcast Amanda Lang spoke with Ian Bremmer, founder of Eurasia Group and GZERO Media, and he had some provocative things to say about how Canada might be its own adversary when it comes to keeping a united front in dealing with the United States. And in her Takeaway, Amanda looks at the issues associated with Delta Airlines' plan to use artificial intelligence to implement dynamic pricing for its airline tickets.
Globe and Mail
19 minutes ago
- Globe and Mail
Down on dividend investing? Here's why you shouldn't be
I hope you're sitting down, because I have some shocking news to share: Not everyone loves dividends. I know, crazy, right? Who could possibly be against receiving regular cash payments for doing absolutely nothing to earn them? Dividend critics offer myriad reasons for their aversion to watching free money pile up in their accounts. Dividend companies are slow-growing dinosaurs, they say. Dividends stick investors with unnecessary taxes. Dividends don't necessarily create wealth but simply return investors' own capital. Some critics have even gone so far as to label dividend investing a cult. Today, I'm going to respond to these and other criticisms of my favourite investing strategy, starting with that last allegation. Okay, I admit it. Dividend investors believe in doomsday prophecies and engage in animal sacrifices. Who doesn't? But that's where the cultish behaviour ends. Unlike in an actual cult, we don't demand slavish devotion to a person or doctrine. Dividend investors are free to hold other asset classes such as growth stocks and fixed-income securities. We believe in diversification because we know that dividend investing has worked very well at times, but less well at other times. The cult of dividend investing faces a crisis of faith That's why I always remind investors to supplement their dividend holdings with index exchange-traded funds. ETFs that track the S&P 500, for example, provide exposure to sectors such as technology that don't generally pay big dividends but have produced outstanding capital gains. As much as I love dividends, l also believe in having a well-rounded portfolio. It depends on what time period you're looking at. Let's compare two exchange-traded funds, the iShares Canadian Select Dividend Index ETF (XDV) and the iShares Core S&P/TSX Capped Composite Index ETF (XIC). For the three years ended June 30, XDV posted a total annualized return, including dividends, of about 12.9 per cent, lagging XIC's return of 16 per cent. This shouldn't be surprising, given that interest rates rose sharply over that period as central banks tried to tame inflation. Rising rates typically compresses dividend stock valuations. But the picture changes dramatically if we look at just the past year, when interest rates were no longer rising, but falling. The dividend ETF came out on top with a total return of 32.5 per cent, compared with 26.2 per cent for the benchmark index ETF. There have been plenty of other periods when dividend stocks outperformed the broader market, and there will probably be more in the future. Critics point out – correctly – that when a dividend is paid (or, more accurately, when the dividend record date arrives), the stock's value adjusts downward by an equal amount to reflect the fact that money has gone out the door. It rarely works out precisely that way, because lots of other factors affect stock prices. But does this mean the company is simply returning your own capital to you? No. Seven stocks with growing dividends that will benefit from rate cuts Return of capital (ROC) has a specific meaning in investing. It refers to a distribution that does not consist of income such as dividends, interest or realized capital gains. A dividend, by definition, is not a return of capital. Rather, it is paid out of a company's earnings. In other words, when a company sends you a dividend, it is sharing a portion of its profits with you. This is your reward for being a part-owner of the business. With growth stocks that pay no dividends, on the other hand, you'll need to sell shares to generate cash – something not everyone is comfortable doing. If you don't need the cash from dividends, you can always enroll your shares in a dividend reinvestment plan so your money continues to compound, or you can manually reinvest your dividends elsewhere. Yes, if you hold dividend stocks in a non-registered account, you'll likely have to pay some tax, which you could avoid if you invested in a growth company that reinvested all of its cash internally instead. The good news is that dividends are taxed at favourable rates thanks to the dividend tax credit (DTC). If your income is low enough, you'll pay very little, if any, tax on dividends. In many provinces, the tax rate on dividends is actually negative in the lowest income brackets. Because the DTC is a non-refundable tax credit, the government won't send you a cheque for the negative tax. But you can use the credit to offset your other taxes owing. Dividends are almost as old as capitalism itself. The practice goes all the way back to the early 1600s, when the Dutch East India Company paid the first dividend – initially in spices, and later in cash – under pressure from investors who complained about the company's poor allocation of capital. Nowadays, dividends are virtually impossible to avoid. The vast majority of the biggest companies on the S&P/TSX Composite Index – including banks, pipelines, railways, energy producers and insurers – pay dividends. If these companies suddenly stopped paying them, shareholders would revolt. The powerful dividend benefit nobody talks about Investors want dividends, not just for financial reasons, but for the psychological benefits as well. During periods of extreme volatility, receiving a regular flow of dividend income can help investors resist the urge to sell, which could sabotage their long-term financial goals. Adding to investors' peace of mind, dividend-paying companies are 'typically well-established, soundly managed companies with stable businesses,' RBC Global Asset Management said in a report. 'Moreover, many companies are able to grow their earnings and reward investors by increasing their dividend payouts, which can lead to share-price gains and help income investors stay ahead of inflation.' Finally, companies that increase their dividends regularly – which is the holy grail for dividend investors – have also outperformed the broader stock market over long periods, with lower volatility, RBC said. With that, I raise my glass to dividends. And, for the record, it isn't filled with cyanide-laced Kool-Aid. E-mail your questions to jheinzl@ I'm not able to respond personally to e-mails but I choose certain questions to answer in my column.
